Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy.

Biomarkers Clinical Trials as Topic Hepatitis B Surface Antigens / analysis Hepatitis D, Chronic / drug therapy Humans Lipopeptides / therapeutic use Liver / pathology Nucleic Acids / therapeutic use Piperidines / therapeutic use Polymers / therapeutic use Pyridines / therapeutic use RNA, Viral / analysis Treatment Outcome
Hepatitis D New treatment approaches Surrogate marker Treatment endpoints

Journal

Journal of hepatology
ISSN: 1600-0641
Titre abrégé: J Hepatol
Pays: Netherlands
ID NLM: 8503886

Informations de publication

Date de publication:
05 2019
Historique:
received: 07 09 2018
revised: 18 12 2018
accepted: 20 12 2018
entrez: 16 4 2019
pubmed: 16 4 2019
medline: 4 9 2020
Statut: ppublish

Résumé

Chronic hepatitis delta represents the most severe form of chronic viral hepatitis. The current treatment of hepatitis delta virus (HDV) infection consists of the use of interferons and is largely unsatisfactory. Several new compounds are currently in development for the treatment of HDV infection. However, surrogate markers that can be used to develop clinical endpoints in HDV infection are not well defined. In the current manuscript, we aimed to evaluate the existing data on treatment of HDV infection and to suggest treatment goals (possible "trial endpoints") that could be used across different clinical trials.

Identifiants

DOI: 10.1016/j.jhep.2018.12.022 PMID: 30982526
pubmed: 30982526
pii: S0168-8278(18)32641-2
doi: 10.1016/j.jhep.2018.12.022
pii:
doi:

Substances chimiques

Biomarkers 0
Hepatitis B Surface Antigens 0
Lipopeptides 0
Nucleic Acids 0
Piperidines 0
Polymers 0
Pyridines 0
REP 2139 0
RNA, Viral 0
myrcludex-B 0
lonafarnib IOW153004F

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1008-1015

Investigateurs

A Wranke (A)
L M Pinheiro Borzacov (LM)
C Lobato (C)
S Hamid (S)
E Ceausu (E)
G N Dalekos (GN)
A Turcanu (A)
G A Niro (GA)
F Lubna (F)
M Abbas (M)
P Ingiliz (P)
P Ferenci (P)
T Vanwolleghem (T)
T Hayden (T)
N Dashdorj (N)
A Motoc (A)
S Hardtke (S)

Informations de copyright

Copyright © 2018. Published by Elsevier B.V.

Auteurs

Cihan Yurdaydin (C)

Department of Gastroenterology, Ankara University, Ankara, and Department of Internal Medicine, Koc University, Istanbul, Turkey. Electronic address: cihan.yurdaydin@medicine.ankara.edu.tr.

Zaigham Abbas (Z)

Department of Hepatogastroenterology, Sindh Institute of Urology and Transplantation, Karachi, Pakistan.

Maria Buti (M)

Liver Unit, Hospital Universitario Vall d'Hebron and Ciber-ehd, Instituto Carlos III, Barcelona, Spain.

Markus Cornberg (M)

Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.

Rafael Esteban (R)

Liver Unit, Hospital Universitario Vall d'Hebron and Ciber-ehd, Instituto Carlos III, Barcelona, Spain.

Ohad Etzion (O)

Institute of Gastroenterology and Liver Diseases Soroka University Medical Center Faculty of Health Sciences, Ben-Gurion University of the Negev, Beersheba, Israel.

Edward J Gane (EJ)

Auckland Clinical Studies, Auckland, New Zealand.

Robert G Gish (RG)

Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University Medical Center, Stanford, CA, USA.

Jeffrey S Glenn (JS)

Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University Medical Center, Stanford, CA, USA.

Saeed Hamid (S)

Aga Khan University Hospital, Department of Medicine, Karachi, Pakistan.

Theo Heller (T)

Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.

Christopher Koh (C)

Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.

Pietro Lampertico (P)

CRC "A. M. e A. Migliavacca", Division of Gastroenterology and Hepatology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan, Italy.

Yoav Lurie (Y)

Central Virology Laboratory, Ministry of Health, Chaim Sheba Medical Center, Tel - Hashomer, 52621 Ramat Gan, Israel.

Michael Manns (M)

Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.

Raymundo Parana (R)

Hepatology Centre of the University Hospital Professor Edgar Santos, Federal University of Bahia, Salvador, Brazil.

Mario Rizzetto (M)

Department of Gastroenterology, University of Turin, Turin, Italy.

Stephan Urban (S)

Department of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, Heidelberg, Germany.

Heiner Wedemeyer (H)

Department of Gastroenterology and Hepatology, Essen University Hospital, University of Duisburg-Essen, Essen, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Treating chronic hepatitis delta: The need for...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études cliniques comme sujet › Essais cliniques comme sujet › Treating chronic hepatitis delta: The need for...
questionsmedicales.fr › Facteurs biologiques › Antigènes › Antigènes viraux › Antigènes d'hépatite virale › Antigènes de l'hépatite virale B › Antigènes de surface du virus de l'hépatite B › Treating chronic hepatitis delta: The need for...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Maladie chronique › Hépatite chronique › Hépatite D chronique › Treating chronic hepatitis delta: The need for...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Treating chronic hepatitis delta: The need for...
questionsmedicales.fr › Acides aminés, peptides et protéines › Peptides › Lipopeptides › Treating chronic hepatitis delta: The need for...
questionsmedicales.fr › Système digestif › Foie › Treating chronic hepatitis delta: The need for...
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Acides nucléiques › Treating chronic hepatitis delta: The need for...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pipéridines › Treating chronic hepatitis delta: The need for...
questionsmedicales.fr › Technologie, industrie et agriculture › Produits manufacturés › Matériaux biomédicaux et dentaires › Polymères › Treating chronic hepatitis delta: The need for...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyridines › Treating chronic hepatitis delta: The need for...
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Acides nucléiques › ARN › ARN viral › Treating chronic hepatitis delta: The need for...
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Qualité des soins de santé › Mécanismes d'évaluation des soins de santé › Évaluation des résultats et des processus en soins de santé › Évaluation de résultat (soins) › Résultat thérapeutique › Treating chronic hepatitis delta: The need for...